Clinical Trial Update: A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL [Phase 2]

View source ↗

Summary

A Phase 2 pediatric study to learn more about Inotuzumab Ozogamicin (InO) for first relapse acute lymphoblastic leukemia in children aged 1 to <18; recruitment …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

Sponsor: Pfizer | Conditions: ACUTE LYMPHOBLASTIC LEUKEMIA | Phase 2 | Status: RECRUITING